Monday, December 30, 2024

Nawy and Truecaller Partner to Elevate Customer Experience With Safe, Efficient, and Trusted Business Communication.

 CAIRO - Monday, 30. December 2025

With the Truecaller Customer Experience[CX] solution, Nawy provides users with a trusted, verified, and contextual communication experience.

Transforming the Real Estate landscape with enhanced trust and safety.

(BUSINESS WIRE)--Nawy, the leading prop-tech platform in Africa that simplifies the buying, selling, and real estate investing journey for customers across Egypt, has announced a partnership with Truecaller, the global leader in communication verification and fraud prevention. This collaboration aims to enhance customer trust and elevate the communication experience in the real estate sector through Truecaller’s Customer Experience solution.


Nawy ensures seamless, secure, and transparent communication for customers throughout their real estate buying journey. By leveraging Truecaller’s Verified Business Caller ID-based solution, Nawy enhances its customer outreach with trusted branding elements like the verified badge, brand name, and logo. This ensures customers can quickly recognize and trust Nawy’s calls, leading to a seamless communication experience and improved engagement.


In today’s world consumers are overwhelmed by scams and fraudulent calls, and certain individuals not affiliated with Nawy have been contacting consumers, falsely claiming to represent the company. In light of this, Nawy reaffirms its commitment to providing the highest level of service to customers and ensuring their comfort by avoiding unnecessary disturbances through Truecaller’s Verified Business Caller ID, which also makes every interaction more authentic and memorable.


Using CX capabilities like Call Reason, Nawy adds valuable context to its calls, ensuring customers understand the purpose before answering.


Commenting on the partnership, Mohamed Abou Ghanima, Co-Founder and COO at Nawy, said: “Partnering with Truecaller reinforces the transparency we strive to provide for our customers. Unfortunately, our name has been used by others pretending to represent Nawy in an attempt to leverage the credibility and trust we have worked hard to build with our customers. These individuals have operated in ways that do not align with our values. By addressing this issue and collaborating with Truecaller, we aim to ensure that our customers can confidently identify genuine calls from Nawy representatives.”


Priyam Bose, Global Head of GTM and Developer Products at Truecaller added: "Truecaller is committed to fostering trust and safety in communication. Our Customer Experience solution empowers businesses like Nawy to deliver secure, seamless, and personalized communication, enabling users to engage confidently. We’re thrilled to partner with Nawy to redefine the customer experience in the African real estate ecosystem and look forward to supporting their journey to build trust and drive impactful engagement."


Truecaller’s Customer Experience Solution empowers business calls with brand identity and context, fostering reliable customer communication. Over 2,500 active businesses worldwide have benefited from the Verified Business Caller ID and other advanced communication capabilities. This solution enhances business call efficiency and significantly reduces phone call-related frauds and scams, promoting heightened customer safety in business communications.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20241217954580/en/



Permalink

https://www.aetoswire.com/en/news/20241217954580r1


Contacts

 

press@truecaller.com

Sunday, December 29, 2024

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

 HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and Hypogammaglobulinemia

Administration of Recombinant Human Hyaluronidase Prior to Immunoglobulin Facilitates Subcutaneous Infusion of Larger Volumes, Potentially Reducing Frequency and Giving Patients More Flexibility

Approval Expands Takeda’s Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company’s Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan

 


(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary immunodeficiency (SID)2. The approval marks availability of the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy as a treatment option for appropriate patients in Japan.


HYQVIA is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10% and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20). The administration of rHuPH20 increases the dispersion and absorption of immunoglobulin (IG) in the subcutaneous tissue, allowing larger volumes to be infused in the infusion site. This allows for less frequent dosing compared to other subcutaneous IG products, while avoiding the need for venous access. The ability to infuse a larger infusion volume is expected to increase administration flexibility for patients with agammaglobulinemia or hypogammaglobulinemia by decreasing the dosing frequency to once every 3 or 4 weeks, as compared to weekly or bi-weekly with conventional SCIG treatments.


The approval is based on data from two pivotal Phase 3, open-label, non-controlled studies evaluating the efficacy, safety, tolerability and pharmacokinetics in Japanese subjects with PID (NCT05150340, NCT05513586). In these studies, the efficacy and safety profile of HYQVIA in 16 patients aged 2 years or older in Japan were evaluated based on the results of the clinical trials. The Geo Mean of IgG trough level at the last 3 visits was 9.494g/L and was maintained at level comparable to treatment with intravenous or subcutaneous immunoglobulin (Geo Mean of IgG trough level 9.624g/L). The major adverse reactions were pyrexia 5 patients (31.3%) and infusion site erythema, injection site erythema, infusion site swelling, infusion site pain, and headache (12.5%)1. Data from two Phase 3 clinical trials conducted in patients with PID in North America (NCT00814320, NCT01175213) was also included in the submission.


“We are delighted that HYQVIA, approved in more than 40 countries worldwide, has now been approved in Japan,” said Naoyoshi Hirota, Regional Head of Research & Development for Takeda’s Plasma-Derived Therapies Business Unit in Japan. “The subcutaneous IG therapies currently available in Japan for patients with agammaglobulinemia or hypogammaglobulinemia require infusion once every week or every 2 weeks. We are proud to offer Japanese patients the first and only facilitated subcutaneous treatment option that offers a reduced dosing frequency of every 3 or 4 weeks.”


“There is a high unmet need for plasma-derived therapies (PDTs) in patients in Japan, which is anticipated to increase as education and timely diagnosis rates continue to improve,” said Kristina Allikmets, head of research & development for Takeda’s Plasma-Derived Therapies Business Unit. “The approval of HYQVIA, the first and only facilitated SCIG treatment, is further evidence of Takeda’s commitment to add to the standard of care for patients in Japan. We look forward to continuing to bring new therapeutic options that support and enhance the experience of patients in our home country throughout the next decade.”


With this approval, Takeda is now able to offer a range of SCIG therapies to patients based on their individual administrative needs, reflecting the company’s commitment to offer patients in Japan a broader choice of treatment options. It also follows the announcement of a significant investment to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan. HYQVIA is also currently under review in Japan for additional indications.


About Agammaglobulinemia or Hypogammaglobulinemia


Agammaglobulinemia is an inherited disorder caused by a gene defect that blocks the growth of normal, mature immune cells called B lymphocytes3. Hypogammaglobulinemia is a condition in which patients have low levels of antibodies due either to inherited genetic conditions (PID) or secondary effects (SID) – like chemotherapy, certain comorbid disorders, or immunosuppressants2. Individuals with any form of antibody deficiency frequently experience recurring and/or severe infections, and immunoglobulin replacement therapy can increase the level of antibodies in the body.


About Primary Immunodeficiency and Secondary Immunodeficiency


Primary immunodeficiency describes a heterogeneous group of more than 480 rare genetic diseases wherein part of the immune system is missing or not functioning properly4. Secondary immunodeficiency is defined as an acquired impairment of the immune response resulting from an underlying condition or factors extrinsic to the immune system. SID may occur as a consequence of malnutrition, metabolic disorders, use of immunosuppressive medications, chronic infections, malignancies, or severe trauma5. Due to their impaired immune system, patients with PID and SID may be more susceptible to infection, and it may take longer to recover from it. In patients with antibody deficiency and increased susceptibility and/or persistent infections, substitution with functional antibodies (immunoglobulin replacement therapy) is the standard of care to support the immune system's functioning5.


About HYQVIA®


HYQVIA is the combination product for subcutaneous injection containing one each vial of Subcutaneous Immunoglobulin 10% (SCIG10%) and Recombinant Human Hyaluronidase PH20 (rHuPH20). As of May 2024, HYQVIA has been approved in more than 40 countries worldwide.


HYQVIA Product Overview in Japan


Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.


Important Notice


For the purposes of this notice, “press release” means this document, any oral presentation, any question-and-answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


Forward-Looking Statements


This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


Medical Information


This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


______________________________

REFERENCES

1 HYQVIA 10% Subcutaneous Injection Set Package Insert in Japan.

2 Pimenta et al. Hypogammaglobulinemia: a diagnosis that must not be overlooked. BJMBR. 2019;52(10): e8926.

3 National Organization for Rare Disorders https://rarediseases.org/rare-diseases/agammaglobulinemia/

4 Tangye et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473-1507.

5 Tuano KS, Seth N, Chinen J. Secondary immunodeficiencies: An overview. Ann Allergy Asthma Immunol. 2021;127(6):617-626.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20241219442534/en/



Permalink

https://www.aetoswire.com/en/news/2712202443786


Contacts

Media:


International Media

Kristine Kelly

Kristine.Kelly@takeda.com

+41 79 268 68 21


Japanese Media

Shigeyuki Matsui

Shigeyuki.Matsui@takeda.com

+81 (80) 3594-2460

Friday, December 27, 2024

Leading Travel Marketplace WINGIE Unveils Key Travel Insights for 2024

 

DUBAI, United Arab Emirates and RIYADH, Saudi Arabia, Dec. 25, 2024 (GLOBE NEWSWIRE) -- The leading online travel marketplace, WINGIE, experienced a remarkable growth in 2024, with bookings doubling compared to 2023. It reflects the increasing demand for travel, supported by data showing a steady rise in bookings, heightened traveler activity, and growing consumer confidence in global mobility.

WINGIE’s data revealed an average basket amount of $191, with Cairo emerging as the most popular destination, accounting for 28% of total bookings. Riyadh followed with 14%, Jeddah with 11%, Dammam with 10%, and Dubai with 7%. The busiest travel routes included Riyadh to Jeddah, which claimed 14% of bookings, followed by Jeddah to Cairo at 12%, Jeddah to Riyadh at 10%, and Cairo to Jeddah at 9%.

This year also saw incredible value for budget-conscious travelers. The most affordable ticket was priced at just $7.95 for a Tashkent to Samarkand flight, while the most expensive reached $11,562 for a Jeddah to London route.

Solo travel emerged as a dominant trend, with 74% of users opting to travel alone, while the remaining 26% traveled in groups of two or more. Booking behavior highlighted a preference for one-way tickets, which 57% of travelers chose, while roundtrip tickets accounted for 43%.

Wingie also provided insights into its user demographics. Men represented 63% of its customers, with women making up 37%. Additionally, 90% of its travelers were adults, 8% were children, and 2% were infants.

As a trusted platform connecting people with their dream destinations, WINGIE continues to lead the way in offering seamless and affordable travel experiences.

About Wingie Enuygun Group

Wingie Enuygun Group is a leading travel marketplace in the MENA region, specializing in flights through its platforms wingie.com, sa.wingie.com, wingie.ae and enuygun.com. The company offers a comprehensive range of travel products including flights, hotels, rental cars and bus tickets. Recognized for its innovation, Wingie Enuygun Group is at the forefront of the MENA online travel space, pioneering technological advancements and driving digital transformation within the industry.

Wingie leverages advanced AI technology to provide a seamless user experience, featuring virtual interlining for flights and a diverse array of airline tickets and travel content. The platform is available in six languages, employs over 400 people, and attracts approximately 200 million visitors annually, reaffirming its position as a premier choice for travelers.

Contact: marketing@wingie.com


Copyright © 2024 GlobeNewswire, Inc.

Thursday, December 26, 2024

Swvl to Provide Last-Mile Shuttle Services for SAB Bank Following Riyadh Metro Launch

 

DUBAI, United Arab Emirates, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Swvl Holdings Corp (“Swvl” or the “Company”) (Nasdaq: SWVL), a leading technology provider of enterprise and government mobility solutions, is collaborating with Saudi Awwal Bank (SAB Bank) to launch its last-mile shuttle operations in Riyadh, Saudi Arabia. This initiative builds on the successful launch of the Riyadh Metro and aims to bridge first- and last-mile connectivity gaps, ensuring seamless access for SAB employees to the city's new metro system.

SAB Bank, one of Saudi Arabia’s leading financial institutions, is leveraging Swvl’s first- and last-mile shuttle services to streamline employee commutes. Swvl provides shuttle buses that connect SAB employees to and from the nearest metro stations, ensuring a smooth and enhanced transportation experience.

Powered by Swvl’s proprietary technology, the first- and last-mile shuttle services are designed to address critical connectivity gaps between business hubs and metro stations. By integrating virtual stops, Swvl brings commuters closer to Riyadh Metro stations, eliminating the inconvenience of long walks and ensuring a smooth transition to and from the metro. This service plays a crucial role following the metro launch, as it enhances accessibility, encourages public transport adoption, and provides a reliable, convenient alternative to private vehicles.

The Riyadh Metro has officially commenced operations, marking a significant milestone in the city's urban mobility transformation. The phased launch began on December 1, 2024. This comprehensive network encompasses six lines, covering a total of 176 kilometers and featuring 85 stations, including four main stations. The Riyadh Metro is designed to provide a sustainable, reliable, and efficient alternative to private vehicles, aiming to reduce traffic congestion and enhance connectivity across the capital.

Mostafa Kandil, CEO of Swvl, stated: "We are proud to support Riyadh’s transformation into a world-class urban center through this collaboration with SAB Bank. By addressing the critical first- and last-mile challenges, Swvl provides commuters with smarter and more accessible mobility solutions."

About Swvl

Swvl is a leading provider of technology-driven mobility solutions for enterprises and governments. Its technology enhances transit system efficiency, delivering safer, more reliable, and sustainable transportation solutions.

For additional information about Swvl, please visit www.swvl.com.

Forward-Looking Statements

This press release contains “forward-looking statements'' relating to future events. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook,” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events and other statements that are not historical facts. For example, Swvl is using forward-looking statements when it discusses the continued provision of shuttle buses to SAB employees and the ability to provide commuters with smarter and more accessible mobility solutions. These statements are based on the current expectations of Swvl’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Swvl. These statements are subject to a number of risks and uncertainties regarding Swvl’s business, and actual results may differ materially. In addition, forward-looking statements provide Swvl’s expectations, plans, or forecasts of future events and views as of the date of this communication. Swvl anticipates that subsequent events and developments could cause Swvl’s assessments and projections to change. However, while Swvl may elect to update these forward-looking statements in the future, Swvl specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Swvl’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon any forward-looking statements. Except as otherwise required by law, Swvl undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website, www.sec.gov, and in subsequent SEC filings.

Contact
Investor.relations@swvl.com


Copyright © 2024 GlobeNewswire, Inc.

LambdaTest Unveils Next-Generation SmartUI Experience for Visual Testing


 NOIDA, India & SAN FRANCISCO - 

LambdaTest unveils its redesigned SmartUI experience, transforming visual testing with seamless navigation, precise controls, and enhanced workflows.


(BUSINESS WIRE) -- LambdaTest, a leading cloud-based unified testing platform has announced the general availability of its reimagined SmartUI screenshot page. This new update is all set to transform visual testing workflows, delivering a seamless, intuitive, and powerful experience tailored to the needs of testers and developers worldwide.


The redesigned SmartUI interface introduces groundbreaking enhancements that prioritize user efficiency and precision. From the new pinch-to-zoom functionality for precise screenshot inspection to a streamlined navigation system featuring a side drawer for quick browsing, every detail has been thoughtfully crafted to improve productivity. The refreshed design also offers a cleaner, more spacious layout, ensuring that users can focus on what matters most—their screenshots.


Smarter workflows now empower users with an intuitive grouping of related functions, while effortless variant switching simplifies the process of comparing test results. The upgraded keyboard shortcuts and dual-side diff controls further amplify testing precision and speed, making this release a game-changer for visual testing.


“Every feature in the redesigned SmartUI page stems from listening to our users and understanding the challenges they face in real-world testing scenarios,” said Mayank Bhola, Co-Founder and Head of Products at LambdaTest. “We’ve gone beyond just improving functionality—we’ve focused on crafting an experience that makes visual testing more efficient and enjoyable.”


LambdaTest’s SmartUI enhancements underscore its commitment to continuous innovation and delivering tools that empower testers and developers to achieve their best work. With this latest release, LambdaTest sets a new benchmark in visual testing excellence, reaffirming its leadership in the digital testing landscape.


For more information about SmartUI and the updated features, visit https://www.lambdatest.com/lp/smart-visual-ui-testing


About LambdaTest


LambdaTest is an intelligent and omnichannel software quality assurance platform that enables businesses to accelerate time to market through AI-powered cloud-based test authoring, orchestration, and execution. Over 10,000+ enterprise customers and 2+ million users across 130+ countries rely on LambdaTest for their testing needs.


Browser & App Testing Cloud allows users to run both manual and automated tests of web and mobile apps across 5000+ different browsers, real devices, and operating system environments.


HyperExecute helps customers run and orchestrate test grids in the cloud for any framework and programming language at blazing-fast speeds to reduce quality test time, helping developers build software faster.


For more information, please visit, https://lambdatest.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20241223111153/en/



Permalink

https://www.aetoswire.com/en/news/2412202443769


Contacts

press@lambdatest.com

Wednesday, December 25, 2024

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results

 SPRING, Texas - Tuesday, 24. December 2024 AETOSWire Print 


The Company generated net sales of $41.6 million for the quarter and $113.4 million year-to-date

Income before income taxes of $5.1 million for the quarter and $13.2 million year-to-date

Backlog of $114.2 million at October 31, 2024, compared to $68.5 million at January 31, 2024

 


(BUSINESS WIRE) -- Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024.


"Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield.


“Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue based upon prior years’ revenues. The continual strengthening of our backlog over the past two quarters is encouraging and provides a sense of optimism heading into next year. Additionally, backlog at the end of the third quarter represents the highest level since transitioning from MFRI to Perma-Pipe, which occurred in March 2017,” Mr. Mansfield continued.


“Our third quarter and fiscal 2024 year-to-date results continue to reflect exceptional performance, which has remained consistent throughout the year. It is worth noting that our net income attributable to common stock for the nine months ended October 31, 2024, represents the highest level of earnings on a year-to-date basis since transitioning from MFRI to Perma-Pipe,” said Mr. Mansfield.


“We are pleased with the level of business activity we have experienced and continue to see, as supported by the significant rise in backlog and share price. The increases in infrastructure spending in Saudi Arabia, India, and the U.A.E., represent key drivers of our overall improvement, for which the strength of our financial results further enables us to continue to execute on strategic initiatives,” concluded Mr. Mansfield.


Third Quarter Fiscal 2024 Results


Net sales were $41.6 million and $45.7 million in the three months ended October 31, 2024 and 2023, respectively. The decrease of $4.1 million, or 9%, was a result of the timing of project execution.


Gross profit was $14.1 million, or 34% of net sales, and $13.2 million, or 29% of net sales, in the three months ended October 31, 2024 and 2023, respectively. The increase of $0.9 million, was driven primarily by better margins due to product mix.


General and administrative expenses were $7.3 million and $5.7 million in the three months ended October 31, 2024 and 2023, respectively. The increase of $1.6 million, was due to higher payroll expenses and professional fees in the quarter.


Selling expenses were $1.2 million and $1.5 million in the three months ended October 31, 2024 and 2023, respectively. The decrease of $0.3 million, was due to lower payroll expense in the quarter.


Net interest expense remained consistent and was $0.5 million and $0.6 million in the three months ended October 31, 2024 and 2023, respectively.


Other expense was $0.1 million and $0.5 million in the three months ended October 31, 2024 and 2023, respectively. The decrease of $0.4 million, was due primarily to exchange rate fluctuations in foreign currency transactions.


The Company's ETR was 32% and 31% in the three months ended October 31, 2024 and 2023, respectively. The change in the ETR is due to the ability to recognize tax benefits on losses in the United States in the current year whereas the prior year had a full valuation allowance and changes to the mix of income and loss in various jurisdictions.


Net income attributable to common stock was $2.5 million and $1.9 million in the three months ended October 31, 2024 and 2023, respectively. The increase of $0.6 million, was mainly due to better project execution in the quarter.


Fiscal 2024 Year-to-Date Results


Net sales were $113.4 million and $110.5 million in the nine months ended October 31, 2024 and 2023, respectively. The increase of $2.9 million, or 3%, was a result of increased sales volumes in the Middle East.


Gross profit was $38.1 million, or 34% of net sales, and $29.4 million, or 27% of net sales, in the nine months ended October 31, 2024 and 2023, respectively. The increase of $8.7 million, was driven primarily by better margins due to product mix.


General and administrative expenses were $19.5 million and $16.4 million in the nine months ended October 31, 2024 and 2023, respectively. The increase of $3.1 million, was due to higher payroll expenses and professional fees.


Selling expenses were $3.8 million and $4.2 million in the nine months ended October 31, 2024 and 2023, respectively. The decrease of $0.4 million, was due to lower payroll expenses.


Net interest expense was $1.5 million and $1.8 million in the nine months ended October 31, 2024 and 2023, respectively. The decrease of $0.3 million, was due primarily to declining interest rates on certain variable rate debt.


Other expense was $0.2 million and $0.4 million in the nine months ended October 31, 2024 and 2023, respectively. The change was due primarily to exchange rate fluctuations in foreign currency transactions.


The Company's ETR was 28% and 49% in the nine months ended October 31, 2024 and 2023, respectively. The change in the ETR is due to the ability to recognize tax benefits on losses in the United States in the current year whereas the prior year had a full valuation allowance and changes to the mix of income and loss in various jurisdictions.


Net income attributable to common stock was $7.2 million and $1.8 million in the nine months ended October 31, 2024 and 2023, respectively. The increase of $5.4 million, was mainly due to better project execution during the year.


Perma-Pipe International Holdings, Inc.


Perma-Pipe International Holdings, Inc. (the “Company”) is a global leader in pre-insulated piping and leak detection systems for oil and gas gathering, district heating and cooling, and other applications. It uses its extensive engineering and fabrication expertise to develop piping solutions that solve complex challenges regarding the safe and efficient transportation of many types of liquids. In total, the Company has operations at fourteen locations in six countries.


Forward-Looking Statements


Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) fluctuations in the price of oil and natural gas and its impact on customer order volume for the Company's products; (ii) the Company’s ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (iii) decreases in government spending on projects using the Company’s products, and challenges to the Company’s non-government customers’ liquidity and access to capital funds; (iv) the Company’s ability to repay its debt and renew expiring international credit facilities; (v) the Company’s ability to effectively execute its strategic plan and achieve sustained profitability and positive cash flows; (vi) the Company's ability to collect a long-term account receivable related to a project in the Middle East; (vii) the Company’s ability to interpret changes in tax regulations and legislation; (viii) the Company's ability to use its net operating loss carryforwards; (ix) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company’s "over-time" revenue recognition; (x) the Company’s failure to establish and maintain effective internal control over financial reporting; (xi) the timing of order receipt, execution, delivery and acceptance for the Company’s products; (xii) the Company’s ability to successfully negotiate progress-billing arrangements for its large contracts; (xiii) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xiv) the Company’s ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xv) reductions or cancellations of orders included in the Company’s backlog; (xvi) risks and uncertainties specific to the Company's international business operations; (xvii) the Company’s ability to attract and retain senior management and key personnel; (xviii) the Company’s ability to achieve the expected benefits of its growth initiatives; (xix) the impact of pandemics and other public health crises on the Company and its operations; and (xx) the impact of cybersecurity threats on the Company’s information technology systems. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at https://www.sec.gov and under the Investor Center section of our website (http://investors.permapipe.com.)


Additional information regarding the Company's financial results for the three months ended October 31, 2024, including management's discussion and analysis of the Company's financial condition and results of operations, is contained in the Company's Quarterly Report on Form 10-Q for the quarterly period ended October 31, 2024, which will be filed with the Securities and Exchange Commission on or about the date hereof and will be accessible at www.sec.gov and www.permapipe.com. For more information, visit the Company's website.


 

PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


(In thousands, except per share data)


(Unaudited)


   

   

  Three Months Ended

October 31, Nine Months Ended

October 31,

 

2024


2023


2024


2023


Net sales

$


41,563


 


$


45,690


 


$


113,397


 


$


110,489


 


Gross profit

 


14,086


 


 


13,184


 


 


38,077


 


 


29,424


 


   

Total operating expenses

 


8,500


 


 


7,145


 


 


23,214


 


 


20,618


 


   

Income from operations

 


5,586


 


 


6,039


 


 


14,863


 


 


8,806


 


   

Interest expense

 


468


 


 


640


 


 


1,489


 


 


1,788


 


Other expense

 


(50


)


 


(502


)


 


(156


)


 


(350


)


Income before income taxes

 


5,068


 


 


4,897


 


 


13,218


 


 


6,668


 


   

Income tax expense

 


1,615


 


 


1,533


 


 


3,692


 


 


3,257


 


   

Net income

$


3,453


 


$


3,364


 


$


9,526


 


$


3,411


 


Less: Net income attributable to non-controlling interest

 


962


 


 


1,429


 


 


2,303


 


 


1,577


 


Net income attributable to common stock

$


2,491


 


$


1,935


 


$


7,223


 


$


1,834


 


   

Earnings per share attributable to common stock  

Basic

$


0.31


 


$


0.24


 


$


0.91


 


$


0.23


 


Diluted

$


0.31


 


$


0.24


 


$


0.90


 


$


0.23


 


   

Note: Earnings per share calculations could be impacted by rounding.


 

 

PERMA-PIPE INTERNATIONAL HOLDINGS, INC. AND SUBSIDIARIES


CONDENSED CONSOLIDATED BALANCE SHEETS


(In thousands)


(Unaudited)


 

   

  October 31, 2024 January 31, 2024

ASSETS  

Current assets

$


104,405


$


98,818


Long-term assets

 


56,344


 


56,893


Total assets

$


160,749


$


155,711


LIABILITIES AND STOCKHOLDERS' EQUITY  

Current liabilities

$


53,794


$


57,742


Long-term liabilities

 


26,792


 


25,991


Total liabilities

 


80,586


 


83,733


Non-controlling interests

 


8,952


 


6,266


Stockholders' equity

 


71,211


 


65,712


Total liabilities and equity

$


160,749


$


155,711


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20241223777874/en/



Permalink

https://www.aetoswire.com/en/news/2412202443770


Contacts

Perma-Pipe International Holdings, Inc.

David Mansfield, President and CEO

Perma-Pipe Investor Relations

(847) 929-1200

investor@permapipe.com

Tuesday, December 24, 2024

BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference

 

SAN MATEO, Calif.--(BUSINESS WIRE/AETOSWire)-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally.

“As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deliver transformative medicines to cancer patients worldwide,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “This milestone inspires pride in all we have accomplished and fuels our excitement for the future as we advance our innovative hematology franchise and solid tumor pipeline, driving meaningful impact for patients everywhere.”

The Company’s CUSIP number will remain unchanged. In addition, the Company stock codes and stock names for The Stock Exchange of Hong Kong and the STAR Market of the Shanghai Stock Exchange will not change. No action by the Company’s shareholders is required to implement the Nasdaq ticker symbol change.

The Company will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, with a presentation at 1:30 pm PT. The live webcast of the event can be accessed from the Investors section of the Company’s website at http://ir.beigene.com/, https://hkexir.beigene.com/https://sseir.beigene.com/. An archived replay will be available for 30 days following the event.

About BeiGene

BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of nearly 11,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedInX (formerly known as Twitter), Facebook and Instagram.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeiGene’s leadership in oncology; BeiGene’s ability to advance its hematology franchise and solid tumor pipeline and the related impact on patients; and BeiGene’s plans, commitments, aspirations and goals under the caption “About BeiGene.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeiGene’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene’s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

To access BeiGene media resources, please visit our News & Media site.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241223168194/en/

 

*Source: AETOSWire

Contacts

Investor Contact
Liza Heapes
+1 857-302-5663
ir@beigene.com

Media Contact
Kyle Blankenship
+1 667-351-5176
media@beigene.com